Sonoma Pharmaceuticals reports publication highlighting Microdox potential

Sonoma Pharmaceuticals reported a recent publication in the journal Neurourology and Urodynamics highlighting the potential for Microdox in the management of urinary tract infections, or UTIs, in children with neurogenic or non-neurogenic bladder dysfunction. Microdox is a super-oxidized solution based on Sonoma’s patented Microcyn technology intended to treat and prevent infections in the urinary tract and bladder. Microdox is licensed by the Therapeutic Goods Administration in Australia and by Medsafe in New Zealand for the prevention and treatment of UTIs, and is currently available in these countries through Sonoma’s partner, Te Arai BioFarma Ltd. The publication in Neurourology and Urodynamics notes that children with a neurogenic bladder are at risk of developing recurrent urinary tract infections and long-term kidney failure, and that due to an altered lower urinary tract, children may be overtreated for simple bacteriuria, or undertreated for a potentially severe urinary tract infection. The authors posit that this risk necessitates new approaches to UTI management in these patients, who are high users of healthcare and for whom UTIs are a significant health burden. They propose that bladder irrigation with electrochemically activated solutions, such as Microdox, could be a powerful therapeutic option in children who require clean intermittent catheterization, with the potential to significantly approve outcomes for these patients. The article cites evidence from recent clinical trials that, in the short term at least, electrochemically activated solutions are effective in safely preventing asymptomatic bacteriuria with no adverse effects. The authors conclude that multi-center trials will be required to establish potential long-term preventative effects.